Episodic Migraine study: Eptinezumab
Official title A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
ClinicalTrials.gov ID: NCT05897320
What this study is testing
What is Eptinezumab?
An investigational intravenous infusion being studied as a potential treatment to reduce episodic migraine days in pediatric participants. It is designed to bind to and block calcitonin gene‑related peptide (CGRP), a molecule involved in migraine pathways.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to determine whether eptinezumab can lower the number of days with episodic migraine in pediatric participants.
- Who it's for
- Children who have episodic migraine.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 6 to 17
You may be able to join if
- Diagnosis of migraine (with or without aura) according to the International Classification of Headache Disorders, 3rd edition (ICHD-3
- During the 28-day screening period, the participant (and their parent/caregiver, when applicable) must adequately complete the headache eDiary (≥23...
- During the 28-day screening period, the participant must have ≤14 headache days, of which at least 4 are migraine days as documented in the eDiary.
You likely can't join if
- History or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or...
- History of moderate or severe head trauma or other neurological disorder or systemic medical disease that is, in the investigator's opinion, likely...
- Current psychiatric condition that is uncontrolled and/or untreated for a minimum of 6 months prior to the Screening Visit.
- Any other disorder for which the treatment takes priority over treatment of migraine or is likely to interfere with study treatment or impair...
The study team makes the final eligibility decision.
Where it is enrolling
- Stamford, Connecticut, United States
- Gulf Breeze, Florida, United States
- Hialeah, Florida, United States
- Tampa, Florida, United States
- Akron, Ohio, United States
- Cincinnati, Ohio, United States
- San Antonio, Texas, United States
- Norfolk, Virginia, United States
- Milwaukee, Wisconsin, United States
- Córdoba, Córdoba Province, Argentina
- Río Cuarto, Córdoba Province, Argentina
- Rosario, Santa Fe Province, Argentina
- San Miguel de Tucumán, Tucumán Province, Argentina
- Victoria, British Columbia, Canada
- Ajax, Ontario, Canada
- London, Ontario, Canada
- Genoa, Italy
- Pavia, Italy
- Pisa, Italy
- Rome, Italy
+ 23 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 6 years to 17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Stamford, Connecticut, United States; Gulf Breeze, Florida, United States; Hialeah, Florida, United States; Tampa, Florida, United States; Akron, Ohio, United States; Cincinnati, Ohio, United States and 37 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.